Key result
Moderate or greater mitral regurgitation (MR ≥ 2+) was associated with increased 3-year mortality after TAVR compared to MR < 2 (HR 1.62; 95% CI 1.38-1.90).
Why the study?
Does mitral regurgitation etiology and severity impact 3-year mortality and MR improvement in patients undergoing TAVR across different aortic stenosis flow groups?
Cohort (n=2,658)
Does mitral regurgitation etiology and severity impact 3-year mortality and MR improvement in patients undergoing TAVR across different aortic stenosis flow groups?
Hazard Ratio: 1.62 (95% CI 1.38–1.9)
Concomitant moderate or severe mitral regurgitation increases 3-year mortality after TAVR, but the prognostic impact of MR and its improvement varies significantly depending on the underlying aortic stenosis flow subtype.
Background Management of transcatheter aortic valve replacement (TAVR) in aortic stenosis (AS) flow-groups—high-gradient (HG-AS), classical low-flow low-gradient (cLFLG-AS), and paradoxical low-flow low-gradient (pLFLG-AS)—is debated. Concomitant mitral regurgitation (MR) worsens outcomes, but the influence of MR etiology on AS subtypes is unclear. Aims To evaluate the impact of MR etiology and severity on outcomes across AS flow groups in TAVR patients. Methods : A retrospective analysis was performed on 2,658 patients undergoing TAVR (2013–2021). MR was categorized as atrial functional (aFMR), ventricular functional (vFMR), or primary MR (PMR). Outcomes included 3-year mortality, MR improvement, and symptomatic benefit. Results : Out of 2,658 TAVR patients, 531 (20.0%) showed at least moderate MR (MR ≥ 2+) (50.1% male, median age 83.1 years). The fraction of patients with MR ≥ 2+ was highest among cLFLG-AS patients (34.2%). MR etiology varied among AS subtypes, with mostly vFMR in cLFLG-AS (83.0%) and highest rates of aFMR (43%) and PMR (45%) in pLFLG-AS patients. Three-year mortality was significantly affected by MR severity (HR for MR2+ vs. MR < 2 1.62 [1.38-1.90]). Differences in 3-year mortality were found in high-gradient (HG)-AS (HR:1.52 [1.16-1.98]) and pLFLG-AS patients (HR:1.73 [1.24-2.40]), but not in cLFLG-AS patients (HR:1.21 [0.93-1.56]). MR improvement after TAVR was commonly found in HG-AS (67.2%) and least often among pLFLG-AS (48.7%, p = 0.03 compared to HG-AS). While MR improvement was associated with a lower mortality in HG-AS (HR:0.21 [0.10-0.43]) and cLFLG-AS patients (HR:0.48 [0.29-0.79]), this was not the case in pLFLG-AS patients (1.32 [0.67-2.59]). Conclusions MR etiology and severity influence outcomes after TAVR depending on AS flow groups.
No takes yet. Share an insight, caveat, or question.
Doldi et al. (2025) conducted a cohort in Aortic stenosis undergoing TAVR (n=2,658). Moderate or greater mitral regurgitation (MR ≥ 2+) vs. MR < 2 was evaluated on 3-year mortality (HR 1.62, 95% CI 1.38-1.90). Moderate or greater mitral regurgitation (MR ≥ 2+) was associated with increased 3-year mortality after TAVR compared to MR < 2 (HR 1.62; 95% CI 1.38-1.90).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: